Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 59,767 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 59,767 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $44.58, for a total transaction of $2,664,412.86. Following the completion of the transaction, the director owned 2,856,461 shares in the company, valued at approximately $127,341,031.38. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 3.9%

SION stock traded up $1.72 during midday trading on Monday, reaching $45.95. 670,726 shares of the company’s stock traded hands, compared to its average volume of 474,065. The company has a 50-day moving average price of $38.55 and a two-hundred day moving average price of $39.36. Sionna Therapeutics, Inc. has a 52 week low of $11.77 and a 52 week high of $48.45.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.15. As a group, analysts anticipate that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. bought a new position in Sionna Therapeutics in the 1st quarter valued at approximately $667,000. Woodline Partners LP bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth $837,000. Geode Capital Management LLC raised its stake in shares of Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Sionna Therapeutics in the second quarter worth $307,000. Finally, New York State Common Retirement Fund bought a new position in shares of Sionna Therapeutics during the second quarter valued at $118,000.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Citizens Jmp began coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 target price for the company. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, April 27th. Wedbush assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price for the company. Finally, UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.